Anna Gipson
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
-
- Antibiotic Use and Resistance
Papers in
-
- SARS-CoV-2 and COVID-19 Research 3
- Surgery 3
- Kawasaki Disease and Coronary Complications 1
- Organ Transplantation Techniques and Outcomes 1
Anna Gipson
12 papers receiving 1.7k citations
Anna Gipson's Hit Papers
Peers
Comparison fields: 5 of 103
- Infectious Diseases 962
- Applied Microbiology and Biotechnology 50
- Neurology 344
- Internal Medicine 56
- Obstetrics and Gynecology 86
Countries citing papers authored by Anna Gipson
This map shows the geographic impact of Anna Gipson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Gipson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Gipson more than expected).
Fields of papers citing papers by Anna Gipson
This network shows the impact of papers produced by Anna Gipson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Gipson. The network helps show where Anna Gipson may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 5 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 6 | 2023 | 83 | |
| 7 | 2020 | 57 | |
| 8 | 2024 | 26 | |
| 9 | 2023 | 24 | |
| 10 | 2024 | 23 | |
| 11 | 2025 | 5 | |
| 12 | 2025 | 5 | |
| 13 | 2013 | 0 |
About Anna Gipson
Anna Gipson is a scholar working on Infectious Diseases, Surgery, Hepatology, Pulmonary and Respiratory Medicine and Endocrinology, Diabetes and Metabolism, having authored 13 papers that have together received 1.7k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (3 papers), Prostate Cancer Treatment and Research (1 paper), Kawasaki Disease and Coronary Complications (1 paper), Prostate Cancer Diagnosis and Treatment (1 paper), Liver Disease and Transplantation (1 paper), Organ Transplantation Techniques and Outcomes (1 paper), Sexual Differentiation and Disorders (1 paper) and Hormonal and reproductive studies (1 paper). The work is most often cited by research in Infectious Diseases (962 citations), Applied Microbiology and Biotechnology (50 citations), Neurology (344 citations), Internal Medicine (56 citations) and Obstetrics and Gynecology (86 citations). Anna Gipson has collaborated with scholars based in United Kingdom, Australia and Netherlands. Their work appears in journals such as The Lancet, The Lancet Diabetes & Endocrinology, The Lancet Infectious Diseases, JAMA Oncology and The Lancet Child & Adolescent Health.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.